Synthetic Biologics Inc (SYN) Sees Significant Decrease in Short Interest
Synthetic Biologics Inc (NYSE:SYN) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 9,312,299 shares, a decrease of 7.4% from the September 15th total of 10,051,188 shares. Approximately 12.5% of the shares of the stock are short sold. Based on an average trading volume of 350,088 shares, the short-interest ratio is presently 26.6 days.
Shares of Synthetic Biologics (NYSE:SYN) opened at 1.67 on Wednesday. The stock’s market cap is $152.42 million. The company has a 50-day moving average price of $1.69 and a 200-day moving average price of $1.93. Synthetic Biologics has a 1-year low of $0.93 and a 1-year high of $3.09.
Synthetic Biologics (NYSE:SYN) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.02. On average, equities analysts expect that Synthetic Biologics will post ($0.39) earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on SYN shares. Griffin Securities set a $5.80 price target on Synthetic Biologics and gave the stock a “buy” rating in a report on Wednesday, August 31st. BTIG Research started coverage on Synthetic Biologics in a report on Thursday, August 25th. They issued a “buy” rating and a $5.00 price target on the stock. FBR & Co restated a “buy” rating on shares of Synthetic Biologics in a report on Friday, August 5th. Finally, Zacks Investment Research cut Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Thursday, July 7th.
A number of institutional investors have recently modified their holdings of the company. KCG Holdings Inc. acquired a new position in shares of Synthetic Biologics during the second quarter worth about $106,000. Rhumbline Advisers acquired a new position in shares of Synthetic Biologics during the second quarter worth about $126,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Synthetic Biologics during the second quarter worth about $213,000. Teachers Advisors Inc. acquired a new position in shares of Synthetic Biologics during the second quarter worth about $216,000. Finally, Vanguard Group Inc. boosted its position in shares of Synthetic Biologics by 10.5% in the second quarter. Vanguard Group Inc. now owns 2,761,194 shares of the company’s stock worth $4,970,000 after buying an additional 262,551 shares in the last quarter.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.